JPH0564130B2 - - Google Patents
Info
- Publication number
- JPH0564130B2 JPH0564130B2 JP57188921A JP18892182A JPH0564130B2 JP H0564130 B2 JPH0564130 B2 JP H0564130B2 JP 57188921 A JP57188921 A JP 57188921A JP 18892182 A JP18892182 A JP 18892182A JP H0564130 B2 JPH0564130 B2 JP H0564130B2
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- tumor
- chelating agent
- labeled
- cea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 64
- 239000002738 chelating agent Substances 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 13
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims description 12
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 239000002872 contrast media Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 239000012954 diazonium Substances 0.000 claims description 2
- 150000001989 diazonium salts Chemical class 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 229960001484 edetic acid Drugs 0.000 claims 2
- 230000005251 gamma ray Effects 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229960003330 pentetic acid Drugs 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000002494 anti-cea effect Effects 0.000 description 31
- 238000000034 method Methods 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000009826 distribution Methods 0.000 description 11
- 238000003384 imaging method Methods 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 239000011630 iodine Substances 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000003127 anti-melanomic effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000003182 parenteral nutrition solution Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- ULAKFSAOPCUOJB-UHFFFAOYSA-N C1=CC(=CC=C1C(C(=O)O)N(CCN(CC(=O)O)CC(=O)O)CC(=O)O)NC(=O)CBr Chemical compound C1=CC(=CC=C1C(C(=O)O)N(CCN(CC(=O)O)CC(=O)O)CC(=O)O)NC(=O)CBr ULAKFSAOPCUOJB-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000002739 cryptand Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 108091005979 iodinated proteins Proteins 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical class [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000011410 subtraction method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940071566 zinc glycinate Drugs 0.000 description 1
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31528681A | 1981-10-27 | 1981-10-27 | |
| US315286 | 1981-10-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58135820A JPS58135820A (ja) | 1983-08-12 |
| JPH0564130B2 true JPH0564130B2 (fr) | 1993-09-14 |
Family
ID=23223718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57188921A Granted JPS58135820A (ja) | 1981-10-27 | 1982-10-26 | 放射化モノクロン抗体及びそれを有効成分とする造影剤 |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS58135820A (fr) |
| AT (1) | AT392004B (fr) |
| BE (1) | BE894829A (fr) |
| CA (1) | CA1202892A (fr) |
| CH (1) | CH653040A5 (fr) |
| DE (1) | DE3239410A1 (fr) |
| DK (1) | DK164682C (fr) |
| ES (2) | ES516797A0 (fr) |
| FI (1) | FI82379C (fr) |
| FR (1) | FR2515046B1 (fr) |
| GB (1) | GB2109407B (fr) |
| IL (1) | IL67068A0 (fr) |
| IT (1) | IT1153857B (fr) |
| LU (1) | LU84441A1 (fr) |
| NL (1) | NL8204108A (fr) |
| NO (1) | NO169947C (fr) |
| SE (1) | SE8206073L (fr) |
| ZA (1) | ZA827806B (fr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957939A (en) * | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| CA1225930A (fr) * | 1982-06-07 | 1987-08-25 | Otto A. Gansow | Anticorps monoclonaux conjugues avec des chelates metalliques |
| US4741900A (en) * | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| SE8401946L (sv) * | 1983-04-08 | 1984-11-13 | Kureha Chemical Ind Co Ltd | Antikropp mot human prostatacancer |
| GB2140030A (en) * | 1983-04-08 | 1984-11-21 | Kureha Chemical Ind Co Ltd | Monoclonal antibody to human urinary bladder cancer |
| JPS59199636A (ja) * | 1983-04-26 | 1984-11-12 | Nippon Mejifuijitsukusu Kk | 放射性診断剤 |
| US4677058A (en) * | 1983-05-19 | 1987-06-30 | Karl Tryggvason | Detecting malignant cells with monoclonal antibodies specific to type IV collagenase enzyme |
| US4732864A (en) * | 1983-10-06 | 1988-03-22 | E. I. Du Pont De Nemours And Company | Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules |
| JPS60201260A (ja) * | 1984-03-27 | 1985-10-11 | Yamasa Shoyu Co Ltd | 心疾患診断薬 |
| JP2507982B2 (ja) * | 1984-04-10 | 1996-06-19 | 武田薬品工業株式会社 | ヒト癌胎児性抗原反応性モノクロ―ナル抗体の製造法 |
| US4898724A (en) * | 1984-06-04 | 1990-02-06 | The Dow Chemical Company | Organis amine phosphonic acid complexes for the treatment of calcific tumors |
| CA1260827A (fr) * | 1984-08-31 | 1989-09-26 | Richard C. Siegel | Complexes anticorps - ions metalliques |
| US4837003A (en) * | 1984-09-13 | 1989-06-06 | Mallinckrodt, Inc. | Radiolabeled antibody fragments |
| US4659839A (en) * | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| US4897255A (en) * | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US5242679A (en) * | 1985-01-14 | 1993-09-07 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4986256A (en) * | 1985-02-28 | 1991-01-22 | The United States Of America As Represented By The Department Of Health And Human Services | Use of paramagnetic metalloporphyrins as contrast agents for tumors in MRI imaging |
| US4824986A (en) * | 1985-04-26 | 1989-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Metal chelate protein conjugate |
| US4830847A (en) * | 1985-06-28 | 1989-05-16 | The Procter & Gamble Company | Diphosphonate-derivatized macromolecules |
| US4732974A (en) * | 1986-03-05 | 1988-03-22 | Mallinckrodt, Inc. | Metal ion labeling of carrier molecules |
| US4877868A (en) * | 1986-03-12 | 1989-10-31 | Neorx Corporation | Radionuclide antibody coupling |
| US5082930A (en) * | 1986-05-29 | 1992-01-21 | Mallinckrodt Medical, Inc. | Coupling agents for joining radionuclide metal ions with biologically useful proteins |
| US4861869A (en) * | 1986-05-29 | 1989-08-29 | Mallinckrodt, Inc. | Coupling agents for joining radionuclide metal ions with biologically useful proteins |
| US4925804A (en) * | 1986-06-17 | 1990-05-15 | Baxter International Inc. | Interligand metal transfer assay |
| US5246692A (en) * | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US4831175A (en) * | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| FR2604092B1 (fr) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
| CA1340014C (fr) * | 1986-10-27 | 1998-08-25 | Bryan Michael Longenecker | Anticorps monoclonaux marqueurs de carcinomes; leur elicitation avec l'antigene asialo-gmi |
| US5057302A (en) * | 1987-02-13 | 1991-10-15 | Abbott Laboratories | Bifunctional chelating agents |
| US5227474A (en) * | 1987-02-13 | 1993-07-13 | Abbott Laboratories | Bifunctional chelating agents |
| DE3710730A1 (de) * | 1987-03-31 | 1988-10-20 | Schering Ag | Substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel |
| US5177192A (en) * | 1987-04-02 | 1993-01-05 | Centocor, Incorporated | Method for labeling antibodies with a metal ion |
| US5053493A (en) * | 1987-04-02 | 1991-10-01 | Centocor Cardiovascular Imaging Partners, L.P. | Method for labeling antibodies with a metal ion |
| US4838274A (en) * | 1987-09-18 | 1989-06-13 | Air Products And Chemicals, Inc. | Perfluoro-crown ethers in fluorine magnetic resonance imaging |
| US5217704A (en) * | 1987-11-06 | 1993-06-08 | Abbott Laboratories | Methods and materials for the preparation of metal labelled antibody solutions |
| US5648471A (en) * | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| US4867962A (en) * | 1988-02-26 | 1989-09-19 | Neorx Corporation | Functionally specific antibodies |
| US4988496A (en) * | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5075099A (en) * | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5218128A (en) * | 1988-06-15 | 1993-06-08 | Centocor, Inc. | Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom |
| US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
| US5792444A (en) * | 1989-05-09 | 1998-08-11 | The General Hospital Corporation | Labeled chemotactic peptides to image focal sites of infection or inflammation |
| PT590766E (pt) * | 1992-07-31 | 2000-07-31 | Australian Nuclear Science Tec | Complexos metalicos de hidroxiarilo contendo agentes quelantes de acido aminocarboxilico |
| US5807535A (en) * | 1992-07-31 | 1998-09-15 | Australian Nuclear Science & Technology Organisation | Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents |
| US7521531B2 (en) | 1996-08-28 | 2009-04-21 | Immunomedics, Inc. | Methods for the purification of stable radioiodine conjugates |
| US6663866B1 (en) | 1996-08-28 | 2003-12-16 | Immunomedics, Inc. | Stable radioiodine conjugates and methods for their synthesis |
| US6558669B1 (en) * | 1996-08-28 | 2003-05-06 | Immunomedics, Inc. | Stable radioiodine conjugates and methods for their synthesis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5695119A (en) * | 1979-10-29 | 1981-08-01 | University Patents Inc | Method and composition for detecting human cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4323546A (en) * | 1978-05-22 | 1982-04-06 | Nuc Med Inc. | Method and composition for cancer detection in humans |
| US4272503A (en) * | 1978-05-25 | 1981-06-09 | New England Nuclear Corporation | Reductant composition for technetium-99m and method for making technetium-99m labelled ligands |
| AU556548B2 (en) * | 1980-03-03 | 1986-11-06 | Milton David Goldenberg | Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers |
-
1982
- 1982-10-25 FI FI823633A patent/FI82379C/fi not_active IP Right Cessation
- 1982-10-25 GB GB08230356A patent/GB2109407B/en not_active Expired
- 1982-10-25 FR FR8217800A patent/FR2515046B1/fr not_active Expired
- 1982-10-25 NL NL8204108A patent/NL8204108A/nl not_active Application Discontinuation
- 1982-10-25 DE DE19823239410 patent/DE3239410A1/de active Granted
- 1982-10-25 ES ES516797A patent/ES516797A0/es active Granted
- 1982-10-25 NO NO823530A patent/NO169947C/no unknown
- 1982-10-25 AT AT0391682A patent/AT392004B/de not_active IP Right Cessation
- 1982-10-26 LU LU84441A patent/LU84441A1/fr unknown
- 1982-10-26 JP JP57188921A patent/JPS58135820A/ja active Granted
- 1982-10-26 DK DK474182A patent/DK164682C/da active
- 1982-10-26 CH CH6239/82A patent/CH653040A5/de not_active IP Right Cessation
- 1982-10-26 IT IT23932/82A patent/IT1153857B/it active
- 1982-10-26 ZA ZA827806A patent/ZA827806B/xx unknown
- 1982-10-26 IL IL67068A patent/IL67068A0/xx not_active IP Right Cessation
- 1982-10-26 SE SE8206073A patent/SE8206073L/ not_active Application Discontinuation
- 1982-10-26 CA CA000414208A patent/CA1202892A/fr not_active Expired
- 1982-10-27 BE BE0/209345A patent/BE894829A/fr not_active IP Right Cessation
-
1984
- 1984-01-31 ES ES529310A patent/ES8505482A1/es not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5695119A (en) * | 1979-10-29 | 1981-08-01 | University Patents Inc | Method and composition for detecting human cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| FI823633L (fi) | 1983-04-28 |
| DE3239410A1 (de) | 1983-05-19 |
| NL8204108A (nl) | 1983-05-16 |
| IT8223932A0 (it) | 1982-10-26 |
| ES8404857A1 (es) | 1984-05-16 |
| FR2515046A1 (fr) | 1983-04-29 |
| NO169947B (no) | 1992-05-18 |
| ES529310A0 (es) | 1985-05-16 |
| ATA391682A (de) | 1990-07-15 |
| LU84441A1 (fr) | 1983-06-13 |
| FI823633A0 (fi) | 1982-10-25 |
| NO823530L (no) | 1983-04-28 |
| IL67068A0 (en) | 1983-02-23 |
| BE894829A (fr) | 1983-02-14 |
| IT1153857B (it) | 1987-01-21 |
| GB2109407A (en) | 1983-06-02 |
| CH653040A5 (de) | 1985-12-13 |
| FI82379B (fi) | 1990-11-30 |
| SE8206073L (sv) | 1983-04-28 |
| DK474182A (da) | 1983-04-28 |
| GB2109407B (en) | 1985-12-18 |
| ES8505482A1 (es) | 1985-05-16 |
| AT392004B (de) | 1991-01-10 |
| DK164682B (da) | 1992-08-03 |
| JPS58135820A (ja) | 1983-08-12 |
| ES516797A0 (es) | 1984-05-16 |
| FR2515046B1 (fr) | 1985-11-29 |
| DE3239410C2 (fr) | 1991-12-19 |
| CA1202892A (fr) | 1986-04-08 |
| DK164682C (da) | 1992-12-21 |
| FI82379C (fi) | 1991-03-11 |
| NO169947C (no) | 1992-08-26 |
| SE8206073D0 (sv) | 1982-10-26 |
| ZA827806B (en) | 1983-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0564130B2 (fr) | ||
| Garg et al. | Comparative tissue distribution in mice of the α-emitter 211At and 131I as labels of a monoclonal antibody and F (ab′) 2 fragment | |
| Doussal et al. | Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice | |
| Novak-Hofer et al. | Copper-67 as a therapeutic nuclide for radioimmunotherapy | |
| EP0173629A1 (fr) | Complexes d'ions métalliques conjugés avec des anticorps | |
| WO1991014459A1 (fr) | Ligand du type dtpa bifonctionnel | |
| Bernhard et al. | Localization of 111In-and 125I-labeled monoclonal antibody in guinea pigs bearing line 10 hepatocarcinoma tumors | |
| Goodwin et al. | Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system | |
| Fawwaz et al. | Immunoreactivity and biodistribution of indium-111-labeled monoclonal antibody to a human high molecular weight-melanoma associated antigen | |
| Vaidyanathan et al. | N-succinimidyl 3-[211At] astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with α-particle emitting 211At | |
| Sakahara et al. | Localization of human osteogenic sarcoma xenografts in nude mice by a monoclonal antibody labeled with radioiodine and indium-111 | |
| Alauddin et al. | An improved method of direct labeling monoclonal antibodies with 99mTc | |
| Buchsbaum et al. | Comparison of the distribution and binding of monoclonal antibodies labeled with 131-iodine or 111-indium | |
| Epstein et al. | Radioimmunodetection of human B-cell lymphomas with a radiolabeled tumor-specific monoclonal antibody (Lym-1) | |
| CA2066031C (fr) | Methodes de reduction de la retention non recherchee d'immunoconjugues et metabolites obtenus | |
| Gasparini et al. | Tumor imaging of colo‐rectal carcinoma with an anti‐CEA monoclonal antibody | |
| Hansen et al. | Labeling of anti-tumor antibodies and antibody fragments with Tc-99m | |
| EP0090025A4 (fr) | Marquage specifique de glandes mammaires. | |
| JPH09508352A (ja) | 診断及び治療のためのペプチドなしの金属結合システイン、その製造方法並びにその化合物を含有する医薬製剤 | |
| Dienhart et al. | Imaging of non-small cell lung cancers with a monoclonal antibody, KC-4G3, which recognizes a human milk fat globule antigen | |
| Doherty et al. | Behavior of/sup 111/In-labeled F (ab')/sub 2/fragments (19-9) in patients | |
| Endo et al. | Tumor imaging by monoclonal antibodies labeled with radioactive metal ions | |
| Saga et al. | An antibody‐tumor model for the targeting of CA125‐producing gynecologic malignancies | |
| Chopra | Radioiodinated humanized monoclonal antibody A33 [Radioiodinated-huA33 mAb] | |
| Sakamoto et al. | Detection of Locally Recurrent Colorectal Cancer with Radiolabeled Monoclonal Antibody H‐15 |